Levosulpiride

Levosulpiride

Clinical data
ATC code	N05AL07 (WHO)
Identifiers
IUPAC name N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
JSmol)	Interactive image
SMILES CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
InChI InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1 Key:BGRJTUBHPOOWDU-NSHDSACASA-N
NY (what is this?)  (verify)

Levosulpiride, sold under the brand name SULPEPTA , is a potent prokinetic agent of the benzamide class.^[1] It is a selective antagonist of the dopamine D₂ receptors and 5HT4 Agonism ^[2] on both central and peripheral nervous systems. Levosulpiride is claimed to have mood elevating properties.

Chemically, it is the (S)-(−)-enantiomer of sulpiride.

Uses

Levosulpiride is used in the treatment of:

• Psychosis
• Negative symptoms of schizophrenia
• Anxiety disorders
• Dysthymia
• Vertigo
• Dyspepsia
• Irritable bowel syndrome
• Premature ejaculation.

Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.^[3]

Side effects

Side effects include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.^[4] In the U.S., as of 2013 only one case of adverse reaction to levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.^[3] A case of rapid onset resistant dystonia caused by low dose levosulpiride was reported in India.^[5]

Mechanism of action

In contrast to most other neuroleptics which block both

Levosulpiride is a substituted benzamide derivative and a selective dopamine D₂ antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.^[6]

See also

• Sulpiride
• Veralipride
• Benzamide

References